Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cadence Pharmaceuticals Inc CADX

Healthcare Biotechnology

Recent & Breaking News (NDAQ:CADX)

Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire May 2, 2013

Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013

PR Newswire April 25, 2013

Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success

Marketwired March 20, 2013

Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors

PR Newswire March 14, 2013

Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary

PR Newswire March 12, 2013

Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

PR Newswire March 7, 2013

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection

PR Newswire March 6, 2013

Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013

PR Newswire February 28, 2013

Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013

PR Newswire February 26, 2013

Cadence Pharmaceuticals' CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013

PR Newswire February 6, 2013

Free Research Reports on AMD, CADX, MYRX and SWY Issued by the Bedford Report

Marketwired January 24, 2013

Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance

PR Newswire January 23, 2013

Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements

Marketwired January 21, 2013